Logo

American Heart Association

  47
  0


Final ID:

Curbing Anthracycline Toxicity (CON): Dexrazoxane is Not for Everyone

  • Yu, Anthony  ( Memorial Sloan Kettering Cancer Center , New York , New York , United States )
  • Levenson, Joshua  ( Shadyside Medical Building , Pittsburgh , Pennsylvania , United States )
  • Kondapalli, Lavanya  ( University of Colorado SOM , Denver , Colorado , United States )
  • Dent, Susan  ( University of Rochester Medical Center , Rochester , New York , United States )
  • Author Disclosures:
    Anthony Yu: DO have relevant financial relationships ; Researcher:Merck:Active (exists now) ; Consultant:Avacta:Active (exists now) | Joshua Levenson: DO NOT have relevant financial relationships | Lavanya Kondapalli: DO NOT have relevant financial relationships | Susan Dent: DO have relevant financial relationships ; Consultant:Novartis:Active (exists now) ; Consultant:Eli Lilly:Past (completed) ; Consultant:Myocardial Solutions:Active (exists now) ; Consultant:Gilead Health Sciences:Past (completed) ; Consultant:Pfizer:Active (exists now)
Meeting Info:

Scientific Sessions 2025

2025

New Orleans, Louisiana

Session Info:

Viral Controversies in Heart Failure, Cardiomyopathy, and Cardio-Oncology

Saturday, 11/08/2025 , 01:30PM - 02:45PM

Cardiovascular Seminar

More abstracts on this topic:
Ironing Out Infection Risk (CON): IV Iron is More Help Than Harm

Beavers Craig, Gale Stormi, Bagnola Aaron, Mcilvennan Colleen, Peters Laura

Curbing Anthracycline Toxicity (PRO): Dexrazoxane is the Absolute Best

Barac Ana, Asnani Aarti, Beavers Craig, Bell Caitlin

You have to be authorized to contact abstract author. Please, Login
Not Available